CompletedNot Applicable

IMRT Versus 3DCRT for Locally Advanced Rectal Cancer, Prospective Phase II Study.

Israel75 participantsStarted 2018-10-01

Plain-language summary

The goal of this prospective phase II study was to determine whether personalized planning-based nCRT for LARC would indeed decrease small bowel dose, and whether selected plans, specifically prioritizing lower dose to small bowel, would result in lower rates of acute GI toxicity compared with previously reported rates.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with locally advanced rectal adenocarcinoma * Performance status of 0-2 * Adequate hematologic, renal, and hepatic function Exclusion Criteria: * Prior radiotherapy to pelvis * Metastatic disease at diagnosis

What they're measuring

Number of participants with treatment-related gastrointestinal and urinary adverse events as assessed by CTCAE v5.0

Timeframe: 3 months

Trial details

NCT IDNCT06160570

SponsorRabin Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-01-31

View on ClinicalTrials.gov More Rectal Cancer trials